IP Library Granted Patent US 8,293,495
Granted Patent B2
US 8,293,495 · App. 13/218,123 · Granted Oct 23, 2012

Blood-brain barrier model

Assignee: Wisconsin Alumni Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,293,495
App. No.
13/218,123
Granted
Oct 23, 2012
Kind
B2
Abstract

A method of creating a multicellular blood-brain barrier model is disclosed. In one embodiment, the method comprises culturing primary brain microvascular endothelial cells or embryonic stem cell-derived endothelial cells upon a permeable support in the presence of neural progenitor cells.

Claims (12)

1. A method of analyzing the blood-brain barrier permeability characteristics of a model compound comprising the steps of:

a) creating a multicellular blood-brain barrier model by culturing brain microvascular endothelial cells upon a permeable support in the presence of pre-differentiated multipotent neural progenitor cells wherein the endothelial cells form a monolayer wherein the cells are confluent and express and initial transendothelial electrical resistance (TEER) of 20-50 Ohm×cm 2 before exposure to the neural cells, and wherein the pre-differentiated multipotent neural progenitor cells further differentiate into mixtures of astrocytes, neurons and oligodendrocytes, wherein the TEER is greater than 100 Ohm×cm 2 after exposure to the differentiated neural cells and wherein the model is then capable of a TEER of greater than 100 Ohm×cm 2 for a period of at least 72 hours;

b) exposing a model compound to the blood-brain barrier model resulting from step (a), and

c) measuring the permeability of the barrier model to the compound.

2. The method of claim 1 wherein the measurement is by determination of compound concentration in on each side of the brain microvascular endothelial cell monolayer.

3. The method of claim 1 wherein the endothelial cells are isolated from mammalian brain capillaries in step (a).

4. The method of claim 1 wherein the endothelial cells are derived from isolated embryonic stem cells in step (a).

5. The method of claim 1 wherein the TEER is greater than 200 Ohm×cm 2 after exposure to the neural cells in step (a).

6. The method of claim 1 wherein the neural progenitor cells are isolated from mammalian cortices in step (a).

7. The method of claim 6 wherein the neural cells are digested with at least one enzyme to dissociate the cells.

8. The method of claim 1 wherein the neural progenitor cells are grown as free-floating neurospheres before differentiation in step (a).

9. The method of claim 1 wherein the neural cells are removed after the endothelial cells are confluent and wherein the endothelial cells express a TEER of at least 100 Ohm×cm 2 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2013
From: SHUSTA, ERIC V.; SVENDSEN, CLIVE; WEIDENFELLER, CHRISTIAN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 030634/0392 →
CONFIRMATORY LICENSE Recorded Oct 14, 2011
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027063/0120 →
Continuity (3)
Division 11766633 · Jun 21, 2007
Provisional Application 60816033 · Jun 23, 2006
Related Publication 20110312018A1 · Dec 22, 2011